Drug Profile

TI 7006

Alternative Names: MAR-TriTE/ESO1; TI-7006

Latest Information Update: 28 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Timmune Biotech
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
Mechanism of Action Major histocompatibility complex inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2021 No recent reports of development identified for research development in Cancer in China (Parenteral)
14 Sep 2017 Early research in Cancer in China (Parenteral) before September 2017 (Timmune Biotech pipeline, September 2017)
14 Sep 2017 Timmune Biotech plans a phase I trial for Cancer in 2018 (Timmune Biotech pipeline, September 2017)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com